drug_type
RELEVANT_DRUG
intervention_type
antibody-drug conjugate (ADC)
drug_description
An anti-HER2 antibody–drug conjugate that binds ERBB2 and delivers monomethyl auristatin E (MMAE) to tumor cells, inhibiting microtubules and mediating HER2 blockade/ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
disitamab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Disitamab vedotin is an anti‑HER2 (ERBB2) antibody–drug conjugate that binds HER2 on tumor cells, blocks HER2 signaling and mediates ADCC, then is internalized and releases the cytotoxic payload monomethyl auristatin E (MMAE). MMAE inhibits microtubule polymerization, causing G2/M arrest and apoptosis, with potential bystander killing of adjacent cells.
drug_name
Disitamab Vedotin (RC48)
nct_id_drug_ref
NCT06730373